These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8274244)

  • 1. Interleukin-1, TNF alpha and their naturally occurring antagonists in sepsis.
    Moldawer LL
    Blood Purif; 1993; 11(2):128-33. PubMed ID: 8274244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-1 and tumor necrosis factor and their naturally occurring antagonists during hemodialysis.
    Dinarello CA
    Kidney Int Suppl; 1992 Oct; 38():S68-77. PubMed ID: 1328757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine antagonists in aged subjects and their relation with cellular immunity.
    Catania A; Airaghi L; Motta P; Manfredi MG; Annoni G; Pettenati C; Brambilla F; Lipton JM
    J Gerontol A Biol Sci Med Sci; 1997 Mar; 52(2):B93-7. PubMed ID: 9060965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients.
    Rogy MA; Coyle SM; Oldenburg HS; Rock CS; Barie PS; Van Zee KJ; Smith CG; Moldawer LL; Lowry SF
    J Am Coll Surg; 1994 Feb; 178(2):132-8. PubMed ID: 8173722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections.
    van Deuren M; van der Ven-Jongekrijg J; Demacker PN; Bartelink AK; van Dalen R; Sauerwein RW; Gallati H; Vannice JL; van der Meer JW
    J Infect Dis; 1994 Jan; 169(1):157-61. PubMed ID: 8277177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.
    Van Zee KJ; Kohno T; Fischer E; Rock CS; Moldawer LL; Lowry SF
    Proc Natl Acad Sci U S A; 1992 Jun; 89(11):4845-9. PubMed ID: 1317575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of tumor necrosis factor-alpha, interleukin-6, interleukin-1beta, soluble tumor necrosis factor receptors I and II, interleukin-6 soluble receptor, interleukin-1 soluble receptor type II, interleukin-1 receptor antagonist, and protein in the synovial fluid of patients with temporomandibular joint disorders.
    Kaneyama K; Segami N; Sun W; Sato J; Fujimura K
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Mar; 99(3):276-84. PubMed ID: 15716832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8--markers of remission in rheumatoid arthritis during treatment with methotrexate.
    Seitz M; Loetscher P; Dewald B; Towbin H; Rordorf C; Gallati H; Gerber NJ
    J Rheumatol; 1996 Sep; 23(9):1512-6. PubMed ID: 8877917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of inhibitors of tumor necrosis factor alpha and interleukin 1beta in urine and sera of patients with urosepsis.
    Olszyna DP; Prins JM; Buis B; van Deventer SJ; Speelman P; van der Poll T
    Infect Immun; 1998 Aug; 66(8):3527-34. PubMed ID: 9673230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin 1-beta and its receptor antagonist during serious infections.
    van Deuren M
    Eur J Clin Microbiol Infect Dis; 1994; 13 Suppl 1():S12-6. PubMed ID: 7821299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous modulators of TNF and IL-1 response are under partial control of TNF in baboon bacteremia.
    Redl H; Schlag G; Paul E; Bahrami S; Buurman WA; Strieter RM; Kunkel SL; Davies J; Foulkes R
    Am J Physiol; 1996 Nov; 271(5 Pt 2):R1193-8. PubMed ID: 8945953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proinflammatory cytokine inhibitors, TNF-alpha and oxidative burst of polymorphonuclear leukocytes in the pathogenesis of sepsis in newborns.
    Sikora JP; Chlebna-Sokół D; Dabrowska I; Lipczyński D; Chrul S
    Arch Immunol Ther Exp (Warsz); 2001; 49(2):155-61. PubMed ID: 11348020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host-tumor interaction in ovarian cancer. Spontaneous release of tumor necrosis factor and interleukin-1 inhibitors by purified cell populations from human ovarian carcinoma in vitro.
    Burger RA; Grosen EA; Ioli GR; Van Eden ME; Brightbill HD; Gatanaga M; DiSaia PJ; Granger GA; Gatanaga T
    Gynecol Oncol; 1994 Nov; 55(2):294-303. PubMed ID: 7959299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cytokines IL-1beta and IL-1 receptor antagonist, IL-2 and IL-2 soluble receptor-alpha, IL-6 and IL-6 soluble receptor, TNF-alpha and TNF soluble receptor I, and IL10 in drained and systemic blood after major orthopaedic surgery.
    Krohn CD; Reikerås O; Aasen AO
    Eur J Surg; 1999 Feb; 165(2):101-9. PubMed ID: 10192566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group.
    Goldie AS; Fearon KC; Ross JA; Barclay GR; Jackson RE; Grant IS; Ramsay G; Blyth AS; Howie JC
    JAMA; 1995 Jul; 274(2):172-7. PubMed ID: 7596007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cytokines and antagonists in septic shock].
    Girardin E; Dayer JM
    Schweiz Med Wochenschr; 1993 Mar; 123(11):480-91. PubMed ID: 8386392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro.
    Tilg H; Shapiro L; Vannier E; Poutsiaka DD; Trehu E; Atkins MB; Dinarello CA; Mier JW
    J Immunol; 1994 Mar; 152(6):3189-98. PubMed ID: 8144913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.
    Fischer E; Marano MA; Van Zee KJ; Rock CS; Hawes AS; Thompson WA; DeForge L; Kenney JS; Remick DG; Bloedow DC
    J Clin Invest; 1992 May; 89(5):1551-7. PubMed ID: 1533231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells.
    Coclet-Ninin J; Dayer JM; Burger D
    Eur Cytokine Netw; 1997 Dec; 8(4):345-9. PubMed ID: 9459613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M; Zwicker M; Villiger PM
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.